THE IMPORTANCE OF PRECISION DELIVERY IN ACUTE AND CHRONIC LUNG DISEASES
Mechanical Assisted Ventilation (MAV) and Continuous Positive Pressure Ventilation (CPAP) are commonly used respiratory interventions; however new reports1 indicate high levels of treatment-related adverse events, in particular for patients in critical care treated with Invasive Mechanical Ventilation (IMV) during the COVID-19 pandemic.
These insights highlight that optimisation of gas exchange (O2 and CO2) requires balanced ventilation and perfusion of the lungs, in order to effectively support patients with respiratory failure.
Camcon is certain that a precision oxygen delivery device used in spontaneously breathing patients can delay or avoid IMV and reduce risk of the complications caused by respiratory interventions currently used.
BIMOD® is first-of-its-kind that allows precision delivery of oxygen and nitric oxide. It does so by making use of the patient’s own breathing. The pulses of oxygen and nitric oxide are both delivered at the same time at the beginning of each inhaled breath and at a similar flow rate as the patients’ inspiratory flow. This allows the gases to be entrained in the first part of the breath which is carried only to the best ventilated parts of the lung. Here the nitric oxide selectively increases blood flow which in turn enhances the uptake of oxygen. The BIMOD optimises the gas exchange even in patients with severely damaged lungs2.
The key is to optimise gas exchange in the remaining regions of the normal lung using the patient’s own breathing efforts and not increasing intra-thoracic pressure. Gas exchange occurs best when ventilation and perfusion are “well matched”. BIMOD® achieves this through precision dosing, timing and matching the patients’ own inspiratory flow rate.
A prototype is currently in development and it will be tested, put through clinical trials and refined for mass production in time to help patients suffering from the continuing COVID-19 pandemic.